In a rare move for a biotech expert who primarily takes bullish long-term positions, John McCamant has issued short sale recommendations for three stocks in the CRISPR space. The editor of The Medical Technology Stock Letter and contributor to MoneyShow.com explains his concerns about this specialized group while also reiterating a Strong Buy rating for one gene-editing play which does not rely on CRISPR technology.
Biotechnology expert John McCamant deserves special recognition; his top pick from last year rose an astounding 519%. We’ve asked John, and all these other outstanding advisors, to share their updated opinions on these top performing stocks from last year’s Top Picks 2017 report.
Intrexon (XON) has had a very busy few weeks as the company has delivered a slew of positive news, explains John McCamant, editor of The Medical Technology Stock Letter.
This Top Pick for 2017 may very well have the best and broadest early-stage oncology pipeline with 12 drug development candidates, suggests John McCamant, editor The Medical Technology Stock Letter.
One of the keys to long-term biotech investing is finding the big winners and riding them to huge gains, writes Medical Technology Stock Letter editor John McCamant and frequent MoneyShow.com contributor. Medical Technology Stock Letter has had many such winners over the years, including Genentech and Pharmacyclics. We provided multiple entry points to invest in Pharmacyclics starting at $17 and in three-plus years the company was sold to AbbVie for $262 per share or $21 billion. Over the last year and a quarter, our subscribers have been enjoying incredible gains with the Four Horsemen: Esperion Therapeutics. Madrigal Pharmaceuticals, Nektar Therapeutics, Sangamo Therapeutics.
Myovant Sciences Ltd. (MYOV:NYSE) is an emerging biotech leader focused on developing and commercializing innovative therapies for women’s health and endocrine diseases.
Non-alcoholic steatohepatitis, or NASH, is one of the largest disease opportunities we have ever seen, explains John McCamant, editor of The Medical technology Stock Letter.
10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)
As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline.
Esperion (ESPR) hit a grand slam with triple therapy data, submitting an NDA filing and enrollment ahead of schedule, asserts biotech expert John McCamant, editor of The Medical Technology Stock Letter.
The next-generation of cholesterol drugs were approved in 2016; these targeted drugs rapidly reduce LDL cholesterol in a wide variety of patients with cardiovascular disease, notes Jay Silverman, editor of the Medical Technology Stock Letter.
John McCamant, editor The Medical Technology Stock Letter, reviews a favored biotech stock Incyte (INCY), noting that the company will have a very strong presence at the American Society of Hematology (ASH) Annual Meeting 2016 in early December.
